Dr. med. Dirk Manski

 You are here: Urology Textbook > Drugs in Urology > Alpha blocker > Silodosin

Alpha blocker Silodosin: Side Effects and Dosage

Mechanism of Action of Silodosin

Silodosin is a selective alpha1A-blocker with a long half-life and favorable cardiovascular side effects (Cantrell et al., 2010). Please see section general pharmacology of alpha blocker.

figure structural formula of silodosin
Structural formula of silodosin

Indications for Silodosin

Pharmacokinetics of Silodosin

Bioavailability 32%, high plasma protein binding, hepatic metabolization, elimination half life 13 h, biliary and renal excretion of metabolites.

General Side Effects of Alpha Blocker

Decreased side effect profile since silodosin is a selective α1A blocker.

Contraindications of Silodosin

Urological Contraindications:

Conservative treatment of BPH with silodosin is not indicated, if surgical treatment is imperative: chronic urinary retention with renal failure, recurrent hematuria due to prostatic enlargement, recurrent infections and bladder stones.

Cardiac Contraindications:

Hypotension, mechanical heart failure (valvular, pulmonary embolism, pericarditis), congestive heart failure.

Other contraindications:

Silodosin should be paused perioperatively for cataract surgery to prevent an intraoperative floppy iris syndrome.

Specific Contraindications of Silodosin

Dosage of Silodosin

8 mg orally once daily. Reduce dosage to 4 mg in patients with renal insufficiency (<50 ml/min).

Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Cantrell, M. A.; Bream-Rouwenhorst, H. R.; Hemerson, P. & Magera, J. S. Silodosin for benign prostatic hyperplasia.
Ann Pharmacother, 2010, 44, 302-310.

Chapple 2004 CHAPPLE, C. R.: Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44

  Deutsche Version: Silodosin